The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation

Abstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yas Arimi, Narges Zamani, Mamak Shariat, Hossein Dalili
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Betamethasone Late preterm Neonatal outcome Gynecology and obstetrics RG1-991
Acceso en línea:	https://doaj.org/article/26e47b3783b34c219ce623d48f76dbe4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26e47b3783b34c219ce623d48f76dbe4
record_format	dspace
spelling	oai:doaj.org-article:26e47b3783b34c219ce623d48f76dbe42021-11-21T12:32:45ZThe effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation10.1186/s12884-021-04246-x1471-2393https://doaj.org/article/26e47b3783b34c219ce623d48f76dbe42021-11-01T00:00:00Zhttps://doi.org/10.1186/s12884-021-04246-xhttps://doaj.org/toc/1471-2393Abstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008, RR = 1.59 95% CI (1.12–2.27)) and requiring more respiratory support (71% versus 50%, p = 0.002, RR = 1.43 95% CI (1.13–1.80)) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.Yas ArimiNarges ZamaniMamak ShariatHossein DaliliBMCarticleBetamethasoneLate pretermNeonatal outcomeGynecology and obstetricsRG1-991ENBMC Pregnancy and Childbirth, Vol 21, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Betamethasone Late preterm Neonatal outcome Gynecology and obstetrics RG1-991
spellingShingle	Betamethasone Late preterm Neonatal outcome Gynecology and obstetrics RG1-991 Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
description	Abstract Background Prenatal corticosteroid administration in preterm labor is one of the most important treatments available to improve neonatal outcomes; however, its beneficial effects on late preterm infants (after the 34th week of gestation) remained unknown. We aimed to assess the effects of betamethasone on the clinical condition of the late preterm infants born between 34 and 36 weeks of gestation. Methods This retrospective cohort study was performed on 100 consecutive infants born between 34 and 36 weeks of gestation and received betamethasone before delivery as the cases and 100 neonates with the same delivery conditions but without receiving betamethasone. All neonates were followed up within hospitalization to assess the neonatal outcome. Results The neonates receiving betamethasone suffered more from respiratory distress syndrome (49% versus 31%, p = 0.008, RR = 1.59 95% CI (1.12–2.27)) and requiring more respiratory support (71% versus 50%, p = 0.002, RR = 1.43 95% CI (1.13–1.80)) as compared to the control group. There was no difference between the two groups in other neonatal adverse events or death. Conclusion the use of betamethasone in the late preterm period (after 34 weeks of gestation) has no beneficial effects on lung maturity or preventing neonatal adverse outcomes, even may lead to increase the risk for RDS and requiring respiratory support.
format	article
author	Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili
author_facet	Yas Arimi Narges Zamani Mamak Shariat Hossein Dalili
author_sort	Yas Arimi
title	The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
title_short	The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
title_full	The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
title_fullStr	The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
title_full_unstemmed	The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
title_sort	effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation
publisher	BMC
publishDate	2021
url	https://doaj.org/article/26e47b3783b34c219ce623d48f76dbe4
work_keys_str_mv	AT yasarimi theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT nargeszamani theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT mamakshariat theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT hosseindalili theeffectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT yasarimi effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT nargeszamani effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT mamakshariat effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation AT hosseindalili effectsofbetamethasoneonclinicaloutcomeofthelatepretermneonatesbornbetween34and36weeksofgestation
_version_	1718418932027621376

The effects of betamethasone on clinical outcome of the late preterm neonates born between 34 and 36 weeks of gestation

Ejemplares similares